Glyree MV2 Tablet (Glimepiride 2mg / Metformin 500mg / Voglibose 0.2mg)

About Glyree MV 2 mg tablet:

Each uncoated bilayered Glyree MV 2 mg tablet contains Glimepiride 2 mg, Metformin Hydrochloride 500 mg (In prolonged-release form), Voglibose 0.2 mg and Excipients q.s.

Glimepride, voglibose and metformin are classified under Antidiabetic category medications.

Glimepiride sulphonylurea hypoglycemics, which helps to control blood sugar levels (type 2 diabetes mellitus), in addition to a recommended diet, regular physical exercise and weight reduction when these have not worked on their own.

Voglibose is an alpha-glucosidase inhibitor used for lowering post-prandial blood glucose levels in people with type 2 diabetes mellitus.

Metformin improves glucose tolerance in patients with type-2 diabetes (NIDDM), lowering both basal and postprandial plasma glucose. Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.

Hence, the combination of Glimepiride, Metformin sustained-release and Voglibose complements each other and provides better glycemic control in management of type 2 diabetes and probably in the prevention of its associated macrovascular and microvascular complications.

Use of Glyree MV 2 mg tablet:

Glyree MV 2 mg tablet is indicated in third line treatment of Type II diabetes mellitus in adult patients when diet, exercise and the single agents and second line therapy with two drugs do not result in adequate glycemic control.

Related Product

Usage Direction of Glyree MV 2 mg tablet:

• Glyree MV 2 mg tablet is intended for oral use only.
• Glyree MV 2 mg tablet usually administered with food to reduce the gastrointestinal side effects associated with the metformin component.
• Glyree MV 2 mg tablet should be swallowed whole.
• Glyree MV 2 mg tablet must not be split, crushed, or chewed before swallowing.

Precaution & Related Information of Glyree MV 2 mg tablet:

Precaution should be taken & consult with the physician during following conditions-

• Hypersensitivity to this medicine or any of its components.
• Any type of acute metabolic acidosis (such as lactic acidosis, diabetic ketoacidosis, diabetic pre-coma).
• Severe renal failure (GFR less than 30ml/min).
• Acute conditions with the potential to alter renal function such as: (dehydration, severe infection, shock, Intravascular administration of iodinated contrast agents).
• Acute or chronic disease which may cause tissue hypoxia such as: (cardiac or respiratory failure, recent myocardial infarction, shock).
• Hepatic insufficiency.
• Acute alcohol intoxication, alcoholism.
• Patients with severe ketosis or in a state of diabetic coma or precoma.
• Severe infections, before or after operation or with severe trauma.
• Gastrointestinal obstruction or predisposed to it.
• Consult with the physician during pregnancy & lactation.
• Inform the physician if taking any other medications.
• Store at room temperature. Protected from light and moisture.
• Keep all medicines out of reach of children.

Warnings:

• Glyree MV 2 mg tablet should be administered carefully in patients who are receiving other antidiabetic drugs because hypoglycemia may occur. In the initial weeks of treatment, the risk of hypoglycaemia may be increased and necessitates especially careful monitoring.
• Regular monitoring of thyroid-stimulating hormone (TSH) levels is recommended in patients with hypothyroidism. Long-term treatment with metformin has been associated with a decrease in vitamin B12 serum levels which may cause peripheral neuropathy. Monitoring of the vitamin B12 level is recommended.
• Should be administered with caution for the following Patients with history of laparotomy or ileus; patients with chronic intestinal disease accompanied by disturbance in digestion and absorption; patients with aggravating symptoms due to increased generation of intestinal gas (eg, Roemheld syndrome, severe hernia, and stenosis and ulcer of the large intestine) and patients with serious hepatic or renal disorders.